ES2168273T3 - Ligando para el receptor c-kit y metodos de uso del mismo. - Google Patents
Ligando para el receptor c-kit y metodos de uso del mismo.Info
- Publication number
- ES2168273T3 ES2168273T3 ES93910645T ES93910645T ES2168273T3 ES 2168273 T3 ES2168273 T3 ES 2168273T3 ES 93910645 T ES93910645 T ES 93910645T ES 93910645 T ES93910645 T ES 93910645T ES 2168273 T3 ES2168273 T3 ES 2168273T3
- Authority
- ES
- Spain
- Prior art keywords
- methods
- kit
- binding
- presented
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000013521 mastic Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
SE PRESENTA UNA COMPOSICION FARMACEUTICA QUE CONTIENE EL LIGANDO C-KIT (KL) PURIFICADO MEDIANTE LOS METODOS DE LOS SOLICITANTES DE LA PATENTE Y PRODUCIDO SEGUN LOS METODOS RECOMBINANTES LLEVADOS A CABO POR LOS SOLICITANTES DE LA PATENTE JUNTO CON TOROS FACTORES HEMATOPOYETICOS Y UN SOPORTE FARMACEUTICAMENTE ACEPTABLE ASI COMO LOS METODOS DE TRATAMIENTO DE PACIENTES QUE CONSISTEN EN ADMINISTRAR AL PACIENTE LA COMPOSICION FARMACEUTICA DE ESTA INVENCION. EN ESTA INVENCION SE PRESENTAN TERAPIAS COMBINADAS UTILIZANDO EL LIGADO C-KIT (KL) Y UN POLIPEPTIDO DEL LIGANDO C-KIT PURIFICADO (KL), O UN FRAGMENTO SOLUBLE DEL MISMO Y OTROS FACTORES HEMATOPOYETICOS. TAMBIEN SE PRESENTAN LOS METODOS Y COMPOSICIONES PARA EL USO EX-VIVO DEL KL POR SI SOLO O EN UNA TERAPIA COMBINADA. TAMBIEN SE DESCRIBE UN ANTAGONISTA DEL KL MUTADO. TAL ANTAGONISTA PUEDE SER TAMBIEN UNA MOLECULA PEQUEÑA. TAMBIEN SE DESCRIBEN ACIDOS NUCLEICOS ANTISENTIDO AL KL COMO AGENTES TERAPEUTICOS. POR ULTIMO SE DESCRIBEN LAS COMPOSICIONESY LOS METODOS QUE SE BENEFICIAN DEL PAPEL DEL KL EN LOS GAMETOS, CELULAS MASTICAS Y MELANOCITOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87396292A | 1992-04-23 | 1992-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2168273T3 true ES2168273T3 (es) | 2002-06-16 |
Family
ID=25362700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93910645T Expired - Lifetime ES2168273T3 (es) | 1992-04-23 | 1993-04-16 | Ligando para el receptor c-kit y metodos de uso del mismo. |
Country Status (15)
Country | Link |
---|---|
US (1) | US6159461A (es) |
EP (2) | EP1127577A3 (es) |
JP (1) | JP3750819B2 (es) |
KR (1) | KR100313064B1 (es) |
AT (1) | ATE206309T1 (es) |
AU (1) | AU675429B2 (es) |
CA (1) | CA2133982C (es) |
DE (1) | DE69330878T2 (es) |
DK (1) | DK0639979T3 (es) |
ES (1) | ES2168273T3 (es) |
HK (1) | HK1041205A1 (es) |
HU (1) | HU219540B (es) |
PT (1) | PT639979E (es) |
RU (1) | RU2180850C2 (es) |
WO (1) | WO1993021936A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144731B2 (en) | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
US20050276784A1 (en) * | 1990-08-27 | 2005-12-15 | Solan-Kettering Institute For Cancer Research | Ligand for the c-kit receptor and methods of use thereof |
US5525708A (en) * | 1994-03-28 | 1996-06-11 | Cytomed, Inc. | Covalent dimer of kit ligand |
DE4412794A1 (de) * | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens |
WO1996015230A2 (en) * | 1994-11-16 | 1996-05-23 | Amgen Inc. | Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells |
CA2301979A1 (en) * | 1997-09-10 | 1999-03-18 | Uab Research Foundation | Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
WO2002066069A1 (fr) * | 2001-02-20 | 2002-08-29 | Kansai Technology Licensing Organization Co., Ltd. | Remedes contre l'inflammation/les maladies tumorales |
EP1390076A4 (en) * | 2001-04-27 | 2004-12-15 | Xcyte Therapies Inc | Maturation of antigen-presenting cells with activated cells |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
WO2004072264A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof |
US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
EP1722275B1 (en) | 2005-05-10 | 2010-10-27 | Agfa Graphics N.V. | Method for processing lithographic printing plates |
DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
RU2563235C1 (ru) * | 2014-07-29 | 2015-09-20 | Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ увеличения пула стволовых клеток в организме |
CN115043943A (zh) | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
KR102410778B1 (ko) | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014757A1 (fr) * | 1990-03-28 | 1991-10-03 | Nisshin Steel Co., Ltd. | Lubrifiant pour laminage a chaud d'acier inoxydable |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
EP0676470A1 (en) * | 1989-10-16 | 1995-10-11 | Amgen Inc. | Stem cell factor |
WO1992000376A1 (en) * | 1990-06-25 | 1992-01-09 | Immunex Corporation | Mast cell growth factor |
US20030125519A1 (en) * | 1990-08-27 | 2003-07-03 | Peter Besmer | Ligand for the c-kit receptor and methods of use thereof |
US5767074A (en) * | 1990-08-27 | 1998-06-16 | Sloan-Kettering Institute For Cancer Research | Compositions of soluble C-kit ligand and hematopoietic factors |
AU9028791A (en) * | 1990-10-05 | 1992-04-28 | President And Fellows Of Harvard College | Detection and isolation of ligands |
CA2107897A1 (en) * | 1991-04-09 | 1992-10-10 | Ronald Hoffman | System and process for supporting hematopoietic cells |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US6001803A (en) * | 1992-04-23 | 1999-12-14 | Sloan-Kettering Institute For Cancer Research | Composition of c-kit ligand, GM-CSF, and TNF-α and method of use |
-
1993
- 1993-04-16 JP JP51932293A patent/JP3750819B2/ja not_active Expired - Fee Related
- 1993-04-16 HU HU9403054A patent/HU219540B/hu not_active IP Right Cessation
- 1993-04-16 AT AT93910645T patent/ATE206309T1/de not_active IP Right Cessation
- 1993-04-16 RU RU94046426/14A patent/RU2180850C2/ru active
- 1993-04-16 AU AU41065/93A patent/AU675429B2/en not_active Ceased
- 1993-04-16 EP EP01104932A patent/EP1127577A3/en not_active Withdrawn
- 1993-04-16 DE DE69330878T patent/DE69330878T2/de not_active Expired - Fee Related
- 1993-04-16 EP EP93910645A patent/EP0639979B1/en not_active Expired - Lifetime
- 1993-04-16 CA CA002133982A patent/CA2133982C/en not_active Expired - Lifetime
- 1993-04-16 ES ES93910645T patent/ES2168273T3/es not_active Expired - Lifetime
- 1993-04-16 PT PT93910645T patent/PT639979E/pt unknown
- 1993-04-16 DK DK93910645T patent/DK0639979T3/da active
- 1993-04-16 WO PCT/US1993/003640 patent/WO1993021936A1/en active IP Right Grant
-
1994
- 1994-10-24 KR KR1019940703793A patent/KR100313064B1/ko not_active IP Right Cessation
-
1997
- 1997-07-23 US US08/898,982 patent/US6159461A/en not_active Expired - Lifetime
-
2002
- 2002-02-26 HK HK02101477.8A patent/HK1041205A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HU219540B (hu) | 2001-05-28 |
US6159461A (en) | 2000-12-12 |
EP0639979A1 (en) | 1995-03-01 |
KR950701226A (ko) | 1995-03-23 |
EP1127577A3 (en) | 2002-11-27 |
EP1127577A2 (en) | 2001-08-29 |
DE69330878D1 (de) | 2001-11-08 |
HUT70696A (en) | 1995-10-30 |
AU4106593A (en) | 1993-11-29 |
CA2133982C (en) | 2008-02-12 |
HK1041205A1 (zh) | 2002-07-05 |
PT639979E (pt) | 2002-03-28 |
AU675429B2 (en) | 1997-02-06 |
DE69330878T2 (de) | 2002-05-29 |
JP3750819B2 (ja) | 2006-03-01 |
ATE206309T1 (de) | 2001-10-15 |
JPH07508721A (ja) | 1995-09-28 |
RU94046426A (ru) | 1997-01-10 |
EP0639979B1 (en) | 2001-10-04 |
KR100313064B1 (ko) | 2002-04-06 |
EP0639979A4 (en) | 1996-10-23 |
HU9403054D0 (en) | 1995-02-28 |
RU2180850C2 (ru) | 2002-03-27 |
DK0639979T3 (da) | 2002-12-02 |
CA2133982A1 (en) | 1993-11-11 |
WO1993021936A1 (en) | 1993-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2168273T3 (es) | Ligando para el receptor c-kit y metodos de uso del mismo. | |
HUT64368A (en) | Ligand to receptor c-kit and method for its utilization | |
NL7601628A (nl) | Biologisch aanvaardbaar keramisch glas en toe- passing van het glas voor het vervaardigen van beenderprotesen, alsmede aldus verkregen protese. | |
PT88641A (pt) | Method for the preparation of an adhesion variant | |
IL125282A (en) | Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases | |
NO985975L (no) | Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav | |
ES8801303A1 (es) | Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido. | |
UA66744C2 (en) | 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections | |
MX9304837A (es) | Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico. | |
NO173998C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater | |
TR199802537T2 (xx) | Peptit t�revleri. | |
AR006401A1 (es) | Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. | |
ES2052893T3 (es) | Preparado de n-acetil-glucosamina para administracion por via bucal. | |
DE69133077D1 (de) | Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung | |
ES2187646T3 (es) | Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. | |
ES8400076A1 (es) | Procedimiento para hidroformilar compuestos olefinicamente insaturados. | |
ES2220256T1 (es) | Albumina humana terapeutica con baja actividad para la fijacion de aluminio. | |
ATE168698T1 (de) | Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten | |
DK0862454T3 (da) | CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner | |
MY103593A (en) | Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation | |
ATE70186T1 (de) | Thyrotropin abgebende hormonanaloge fuer verletzungen am zentralnervensystem. | |
DK0911038T3 (da) | Vandfri sammensætning omfattende lactulose | |
ATE335817T1 (de) | Adhäsionsvarianten | |
AU7370798A (en) | Compositions and methods of therapy for igf-i-responsive conditions | |
IT8222856A0 (it) | Composizione farmaceutica sterile per la somministrazione per via iniettabile della citidindifosfocolina veicolata tramite i liposomi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 639979 Country of ref document: ES |